World-class expertise.
Leading-edge technologies.
Record-breaking success.
We’re taking medicine to new heights.
At Nimbus, exquisite selectivity is at the core of everything we do. From people to targets to molecules to partners, our meticulous choices enable us to successfully design and develop small molecule medicines capable of improving patients’ lives. And we have a track record to prove it.
Discover our unique approach to target selection, computational drug design, translational medicine, and clinical development.
Explore our highly selective small molecule medicines for oncology, immunology, and metabolic indications.
Nimbus Therapeutics to Present First Preclinical Data from Werner Syndrome Helicase Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Nimbus Therapeutics Presents New Positive Monotherapy Phase 1/2 Clinical Data of HPK1 Inhibitor in Treatment of Advanced Solid Tumors at 2024 ASCO Annual Meeting
